Analytical Data
-
基因名
CMAHP
- Application
-
别名
CMAHP；CMAH；Inactive cytidine monophosphate-N-acetylneuraminic acid hydroxylase
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q9Y471
-
表达区间
1-501aa
-
氨基酸序列
MDENNGLLLLELNPPNPWDLQPRSPEELAFGEVQITYLTHACMDLKLGDKRMVFDPWLIGPAFARGWWLLHEPPSDWLERLCQADLIYISHLHSDHLSYPTLKKLAGRRPDIPIYVGNTERPVFWNLNQSGVQLTNINVVPFGIWQQVDKNLRFMILMDGVHPEMDTCIIVEYKGHKILNIVDCTRPNGGRLPMKVALMMSDFAGGASGFPMTFSGGKFTEEWKAQFIKTERKKLLNYKARLVKNLQPRIYCPFAGYFVESHPSDKYIKETNTKNDPNELNNLIKKNSDVITWTPRPGATLDLGRMLKDRTDSKGIIEPPEGTKIYKDSWDFEPYLEILNAALGDEIFLHSSWIKEYFTWAGFKDYNLVVRMIETDEDFNPFPGGYDYLVDFLDLSFPKERPQREHPYEEIHSRVDVIRHVVKNGLLWDELYIGFQTRLQRDPDIYHHLFWNHFQIKLPLTPPNWKSFLMCCEQNGPVILQFSTERTNEPNRNKFSVENKA
-
分子量
63.4 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The research on CMAHP recombinant protein stems from the increasing interest in therapeutic proteins and their role in various biomedical applications. CMAHP, or choline/maize amylopectin hydrolyzing protein, is significant due to its potential use in enzyme replacement therapies and as a biocatalyst in industrial processes. The growing prevalence of metabolic disorders and the need for efficient, sustainable solutions in biotechnology have propelled the investigation into CMAHP. This protein exhibits unique properties, such as specificity and stability, making it an attractive candidate for enhancing bioprocessing applications. Moreover, advances in recombinant DNA technology facilitate the production of CMAHP in host organisms, allowing for better yield and functional analysis. Understanding the structure-function relationship of CMAHP at a molecular level can elucidate its mechanisms of action and optimize its utility in therapeutic contexts. As a result, research on CMAHP recombinant protein offers promising insights into innovative treatment strategies and eco-friendly industrial practices, contributing to advancements in both healthcare and biotechnology sectors.
